PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1175-1180

  Bollineni, Vikram R ^a   Kerner, Gerald S M A ^a   Pruim, Jan ^a,b   Steenbakkers, Roel J H M ^a   Wiegman, Erwin M ^a   Koole, Michel J B ^a   De Groot, Eleonore H ^a   Willemsen, Antoon T M ^a   Luurtsema, Gert ^a   Widder, Joachim ^a   Groen, Harry J M ^a   Langendijk, Johannes A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

18F FAZA; 18F FDG; Oncology; PET; PET CT; Respiratory; Tumor hypoxia

Indexed keywords

FLUOROAZOMYCIN ARABINOSIDE F18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HUMAN; HYPOXIA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; METABOLISM; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR HYPOXIA; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

18F-FAZA; 18F-FDG; ONCOLOGY; PET; PET/CT; RESPIRATORY; TUMOR HYPOXIA;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; TUMOR BURDEN;

EID: 84881426634     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.115014     Document Type: Article

References (35)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717.
2. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) ed. of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706-714.
3. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393-410.
4. Ivan M, Kondo K, Yang H, et al. HIFa targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292:464-468.
5. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
6. Ikeda Y, Taveira-DaSilva AM, Pacheco-Rodriguez G, et al. Erythropoietindriven proliferation of cells with mutations in the tumor suppressor gene TSC2. Am J Physiol Lung Cell Mol Physiol. 2011;300:L64-L72.
7. Walenta S, Salameh A, Lyng H, et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol. 1997;150:409-415.
8. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol Imaging Biol. 2004;6:291-305.
9. 18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol. 2000;27:693-700.
10. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
11. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317-326.
12. 18F] FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34:1566-1575.
13. Higashi K, Ueda Y, Sakurai A, et al. Correlation of glut-1 glucose transporter expression with. Eur J Nucl Med. 2000;27:1778-1785.
14. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2000;35:71-103.
15. Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 2001;42:170-175.
16. 18F-FDG PET. J Nucl Med. 2006;47:1921-1926.
17. 18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51.
18. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
19. Piper J. SU-FF-I-68: Evaluation of an intensity-based free-form deformable 5 registration algorithm. Med Phys. 2007;34:2353-2354.
20. La Macchia M, Fellin F, Amichetti M, et al. Systematic evaluation of three different commercial software solutions for automatic segmentation for adaptive therapy in head-and-neck, prostate and pleural cancer. Radiat Oncol. 2012;7: 160-717X-7-160.
21. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93-100.
22. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: voxel size matters. Acta Oncol. 2008;47:1201-1210.
23. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391-398.
24. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441.
25. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;44:749-754.
26. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode: an analysis of inter-and intratumour heterogeneity. Acta Oncol. 1994;33:383-389.
27. Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;62:545-553.
28. 18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746-3753.
29. 18F]FMISO correlates with radiation therapy outcome in headand-neck cancer patients. Radiother Oncol. 2006;80:151-156.
30. Zips D, Zophel K, Abolmaali N, et al. Exploratory prospective trial of hypoxiaspecific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol. 2012;105:21-28.
31. Mortensen LS, Johansen J, Kallehauge J, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105:14-20.
32. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group-cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol. 2000; 18:1351-1359.
33. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/ unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324-333.
34. van Elmpt W, Hamill J, Jones J, De Ruysscher D, Lambin P, Ollers M. Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours. Eur J Nucl Med Mol Imaging. 2011;38:843-855.
35. Cohade C, Osman M, Marshall LN, Wahl RN. PET-CT: Accuracy of PET and CT spatial registration of lung lesions. Eur J Nucl Med Mol Imaging. 2003;30:721-726.